Figure 2.PL402 reduces Aβ level without affecting the α/β/γ-secretase activity or altering APP processing. (A, B) The measurements of BACE1 (A) and γ-secretase (B) activity by ELISA-based secretase assays after treatment with vehicle (0.1% DMSO), 10μM BSI IV(A), 10μM γ-secretase inhibitor L685,458 or the PL402 at 100μM, 300μM. N=3. (C) Representative image of a western blot showing the expression of α-secretase (ADAM10), BACE1 and γ-secretase complex (NCT, PS1, Pen2) after treatment with vehicle (0.1% DMSO), 100μM TAPI-1, 10μM BSI IV, 10μM L685,458, or 100μM and 300μM PL402 for 24 hours (C). Actin was used as a loading control. The statistical analysis of (C) was presented in Supplementary Figure 2A. N=3 (D–I) Representative image of a western blot showing the levels of mAPP, imAPP, sAPPα, sAPPβ, C99 and C83 after treatment with vehicle (0.1% DMSO), 100μM TAPI-1, 10μM BSI IV, 10μM L685,458, or 100μM and 300μM PL402 for 24 hours (D–F). N=3. (G–I) The quantification analysis of (D–F). The Data are presented as mean ± SEM, n = 3 independent experiments, *p < 0.05, ***p< 0.001 and ****p< 0.0001, analyzed by one-way or two-way ANOVA followed by Bonferroni test.
